NRIX / Nurix Therapeutics, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 15, 2026 NURIX THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 15, 2026 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 8, 2026 NURIX THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 8, 2026 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CL

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update Enrolling Phase 2 DAYBreak CLL-201 bexobrutideg trial designed to support Accelerated Approval in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Enabling Phase 3 DAYBreak CLL-306 bexobrutideg confirmatory trial for full approval in r/r CLL Targeting 2026 IND submiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2026 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934         Filed by the Registrant ☒     Filed by a Party other than the Registrant  ☐         Check the appropriate box:          ☐     Preliminary Proxy Statement  ☐     Confide

ARS

)"(
'(('
')&('
"
,"
#!!''#" +0B78=6C>=


/////////////////////////////////////////////////////////////// //////////////////// #&!
 /////////////////////////////////////////////////////////////// //////////////////// !0A:
#=4
"")
&$#&(
$)&')"(
(#
'(#"

#&
3
#
(
')&('
,"
(
#
 
>A
C74
58B20;
H40A
4=343
">E4<14A

 #&
 (&

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by

AMENDMENT NO. 3 TO THE EQUITY DISTRIBUTION AGREEMENT

EX-10.1 Exhibit 10.1 AMENDMENT NO. 3 TO THE EQUITY DISTRIBUTION AGREEMENT March 6, 2026 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: This Amendment No. 3 to the Equity Distribution Agreement (this “Amendment”) is entered into as of the date first written above by Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), and Pi

Security Type

Calculation of Filing Fee Tables S-3 Nurix Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward In

Up to $413,650,000 Common Stock

424B5 Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-280117 AMENDMENT NO. 1 DATED MARCH 6, 2026 TO PROSPECTUS SUPPLEMENT DATED OCTOBER 31, 2024 (To Prospectus dated June 11, 2024) Up to $413,650,000 Common Stock This Amendment No. 1 to prospectus supplement (the amendment) amends our prospectus supplement dated October 31, 2024 (the prospectus supplement). This amendment s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2026 NURIX THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2026 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 Nurix Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.001 par value per share Other 4,072,299 $ 18.62 $ 75,826,207.38 0.0001381 $ 10,471.60 2 Equ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39398 NURIX THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 28, 2026 NURIX THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 28, 2026 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 202

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class profile in relapsed/refractory CLL 83% objective overall response rate

As filed with the Securities and Exchange Commission on January 28, 2026

As filed with the Securities and Exchange Commission on January 28, 2026 Registration No.

Protein Degraders to Outmatch Cancer and Autoimmune Disease J.P. Morgan Healthcare Conference January 12, 2026 Exhibit 99.1 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as su

jpm2026investorpresentat Protein Degraders to Outmatch Cancer and Autoimmune Disease J.

Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, in

[Nurix Logo] Exhibit 99.2 Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases Execute a pivotal program for potential best-in-class BTK degrader, bexobrutideg, including Phase 2 and confirmatory Phase 3 studies to support global registration in relapsed/refractory chronic lymphocytic l

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 12, 2026 NURIX THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 12, 2026 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Objective response rate (ORR) of 75.0% including thr

[Nurix logo] Exhibit 99.2 Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Objective response rate (ORR) of 75.0% including three very good partial responses (VGPR) in heavily pre-treated Waldenström macroglobulinemia patients With a median follow up

Meeting the Needs of Patients with CLL and WM – Bexobrutideg Clinical Update from ASH 2025 American Society of Hematology December 8, 2025 Exhibit 99.3 This presentation contains statements that relate to future events and expectations and as such co

ash2025investorpresentat Meeting the Needs of Patients with CLL and WM – Bexobrutideg Clinical Update from ASH 2025 American Society of Hematology December 8, 2025 Exhibit 99.

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Ann

[Nurix Logo] Exhibit 99.1 Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 6, 2025 NURIX THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 6, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2025 NURIX THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertise

Exhibit 99.1 [Nurix Logo] Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertise SAN FRANCISCO, November 10, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

EX-99.1 Exhibit 99.1 Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock SAN FRANCISCO, October 22, 2025 – Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in oncology and autoimmune disease, today announced the pricing of its underwri

Security Type

Calculation of Filing Fee Tables S-3 Nurix Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward In

Nurix Therapeutics, Inc. Common Stock, Preferred Stock, Debt Securities, Warrants, Subscription Rights and Units

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-280117 PROSPECTUS SUPPLEMENT (To prospectus dated June 11, 2024) 24,485,799 shares of common stock We are offering 24,485,799 shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Global Market under the symbol “NRIX.” The last reported

NURIX THERAPEUTICS, INC. 24,485,799 Shares of Common Stock Underwriting Agreement

EX-1.1 Exhibit 1.1 NURIX THERAPEUTICS, INC. 24,485,799 Shares of Common Stock Underwriting Agreement October 22, 2025 J.P. Morgan Securities LLC Jefferies LLC Stifel, Nicolaus & Company, Incorporated As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Jefferies LLC 520 Madison Avenue New York, New

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphoc

Exhibit 99.1 [Nurix Logo] Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia 600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New preclinical data support bex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 22, 2025 NURIX THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 22, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 22, 2025 NURIX THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 22, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

Bexobrutideg Investor Update Investor Presentation October 2025 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning

a2025-1019bexdeginvestor Bexobrutideg Investor Update Investor Presentation October 2025 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 18, 2025 NURIX THERAPEUTI

FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-280117 October 22, 2025 Explanatory Note: The following information is substantially identical to information that Nurix Therapeutics, Inc. (the “Company”) filed on Form 8-K filed on October 22, 2025. Because of technical difficulties experienced by a third-party vendor, the Company is also filing this information a

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclini

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a novel IRAK4 degrader in collaboration with Gilead, showing potent pathway inh

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 9, 2025 NURIX THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 9, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC.

Protein Degraders to Outmatch Cancer and Autoimmune Disease Investor Presentation September 2025 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looki

nurixinvestorpresentatio Protein Degraders to Outmatch Cancer and Autoimmune Disease Investor Presentation September 2025 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 3, 2025 NURIX THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 3, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 19, 2025 NURIX THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 19, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiza

Amendment No. 1 to Sublease Agreement, dated as of May 31, 2025, between Janssen Research & Development, LLC and the Registrant

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. FIRST AMENDMENT TO SUBLEASE Nurix Contract No. 11791 THIS FIRST AMENDMENT TO SUBLEASE (this “Amendment”) dated May 31, 2025 (the “Effective Date”) is made by and between Janssen Research &

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2025 NURIX THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 9, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC.

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients wi

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia (WM) Secured $15M license fee as Sanofi extends

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 12, 2025 NURIX THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 12, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macro

[Nurix Logo] Exhibit 99.1 Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM) Complete response achieved in CLL; overall objective response rate of 80.9% in CLL patients and 84.2% in p

Meeting the Needs of Patients with CLL and WM – Bexobrutideg Clinical Update from EHA European Hematological Association Investor Event June 12, 2025 This presentation contains statements that relate to future events and expectations and as such cons

ehainvestorconferencecal Meeting the Needs of Patients with CLL and WM – Bexobrutideg Clinical Update from EHA European Hematological Association Investor Event June 12, 2025 This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 19, 2025 NURIX THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 19, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 8, 2025 NURIX THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 8, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC.

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update NX-5948 assigned the nonproprietary name “bexobrutideg” U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglo

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update NX-5948 assigned the nonproprietary name “bexobrutideg” U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemia Achieved $7M in milestones and a $15M license extension fee from ongoing collaboration with Sanofi Enhanced oversi

Sublease Agreement, dated as of February 21, 2025, between Janssen Research & Development, LLC and the Registrant

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SUBLEASE by and between Janssen Research & Development, LLC, a New Jersey limited liability company and Nurix Therapeutics, Inc., a Delaware corporation SUBLEASE THIS SUBLEASE (“Sublease”)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by

ARS

(!'
&''&
&(%'&
!
+!
" &&"! *1C89>7D?>

 
000000000000000000000000000000000000000000000000000000000000000 00000000000000000000 "%
 000000000000000000000000000000000000000000000000000000000000000 00000000000000000000  1B;
">5
!!(
%#"%'
#(%&(!'
'"
&'"!

"%
4
"
'
&(%'&
+!
'
"

?B
D85
69C31<
I51B
5>454
!?F5=25B

"%
 '%!&

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934         Filed by the Registrant ☒     Filed by a Party other than the Registrant  ☐         Check the appropriate box:          ☐     Preliminary Proxy Statement  ☐     Confide

LETTER

March 19, 2025 Hans van Houte Chief Financial Officer Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco, CA 94158 Re: Nurix Therapeutics, Inc. Form 10-K for Fiscal Year Ended November 30, 2024 File No. 001-39398 Dear Hans van Houte: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of thei

March 13, 2025

March 13, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, DC 20549 Attention: Eric Atallah Kevin Kuhar Re: Nurix Therapeutics, Inc. Form 10-K for Fiscal Year Ended November 30, 2024 File No. 001-39398 Ladies and Gentlemen: We are submitting this letter on behalf of Nurix Therapeutics, Inc. (the “Company”) i

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizat

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors Dr. Baynes has been a member of Nurix’s Medical Advisory Board since 2023

Exhibit 99.1 [Nurix Logo] Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors Dr. Baynes has been a member of Nurix’s Medical Advisory Board since 2023 SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commerci

LETTER

February 28, 2025 Hans van Houte Chief Financial Officer Nurix Therapeutics, Inc. 1700 Owens Street, Suite 205 San Francisco, CA 94158 Re: Nurix Therapeutics, Inc. Form 10-K for Fiscal Year Ended November 30, 2024 File No. 001-39398 Dear Hans van Houte: We have limited our review of your filing to the financial statements and related disclosures and have the following comment. Please respond to th

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.

Filing Fee Table

Calculation of Filing Fee Tables S-8 Nurix Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.001 par value per share Other 3,036,376 $ 19.69 $ 59,786,243.44 0.0001531 $ 9,153.27 2 Equi

As filed with the Securities and Exchange Commission on January 28, 2025

As filed with the Securities and Exchange Commission on January 28, 2025 Registration No.

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the

[Nurix logo] Exhibit 99.1 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th American Society of Hematology Annual Meeting Received PRIME designation from the European Medicines Agency for NX-5948

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39398 NURIX THERAPEUT

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 28, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

Insider Trading Policy

Exhibit 19.1 INSIDER TRADING POLICY THIS POLICY WAS APPROVED BY THE BOARD ON JANUARY 22, 2025 PURPOSE Nurix Therapeutics, Inc. (“Nurix”) believes our stock is valuable. For that reason, Nurix stock options and discounted sales of Nurix stock through our Employee Stock Purchase Plan (“ESPP”) are important parts of our compensation program. If you choose to invest in Nurix stock, there are some rule

Medicines to Outmatch Disease Investor Presentation January 13, 2025 Exhibit 99.2 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements w

Medicines to Outmatch Disease Investor Presentation January 13, 2025 Exhibit 99.2 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in this presentation, the words “anticipate,” “believe,” “c

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 13, 2025 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic

Exhibit 99.1 [Nurix Logo] Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases Initiate a suite of clinical trials in 2025 intended to support global registration of NX-5948 for the treatment of chronic lymphocytic leukemia Expand the development of NX-5948 in additional cancer indications and inflammatory diseases Advance o

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting Durable responses are rapid and deepen on treatment as demonstrated by

EX-99.1 2 nrix20241210formex991ashda.htm EX-99.1 Exhibit 99.1 [Nurix logo] Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting Durable responses are rapid and deepen on treatment as demonstrated by an initial 75.5% Objective Response Rate which increased to 84.2% in patien

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 9, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

Nurix Therapeutics Blazing a New Path in Medicine American Society of Hematology Investor Event December 9, 2024 Exhibit 99.2 2 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and a

Nurix Therapeutics Blazing a New Path in Medicine American Society of Hematology Investor Event December 9, 2024 Exhibit 99.

EX-99

Exhibit 99 Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G.

NRIX / Nurix Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment

SC 13G/A 1 tm2426483d9sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 3)* Nurix Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67080M103 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appr

NRIX / Nurix Therapeutics, Inc. / SANDS ARTHUR T - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 ea0220738-sc13ga1sandsnurix.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nurix Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per shares (Title of Class of Securities) 67080M103 (CUSIP Number) September 30, 2024 (Date of Event Which

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Nurix Therapeutics, In

NRIX / Nurix Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm2427858d6sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) Nurix therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 67080M103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement)

NRIX / Nurix Therapeutics, Inc. / WASATCH ADVISORS INC Passive Investment

SC 13G/A 1 nrix1124.txt SCHEDULE 13G Amendment No. 2 Name of Issuer: Nurix Therapeutics, Inc. Title of Class of Securities: Common Stock CUSIP Number: 67080M103 Item 1: Reporting Person: Wasatch Advisors LP 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 708,377 It

NRIX / Nurix Therapeutics, Inc. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nurix Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 67080M103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

JOINT FILING AGREEMENT

EX-99 2 Rule13DJointFilingAgreement.htm JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Nurix Therapeutics, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(

NRIX / Nurix Therapeutics, Inc. / MORGAN STANLEY - MS AMENDMENT Passive Investment

SC 13G/A 1 NurixTherapeuticsNRIX.txt MS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Nurix Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 67080M103 - (CUSIP Number) September 30, 2024 - (Date Of Event which Requires Filing of this Statement) Check the a

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0

CALCULATION OF FILING FEE TABLE Form 424(b)(5) (Form Type) Nurix Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of Each Class of Securities to be Registered Fee Calcu

Exhibit 107 CALCULATION OF FILING FEE TABLE Form 424(b)(5) (Form Type) Nurix Therapeutics, Inc.

As filed with the Securities and Exchange Commission on October 31, 2024

As filed with the Securities and Exchange Commission on October 31, 2024 Registration No.

2024 Equity Inducement Plan and forms of award agreements

Exhibit 99.1 NURIX THERAPEUTICS, INC. 2024 EQUITY INDUCEMENT PLAN 1.PURPOSE. The purpose of this Plan is to provide incentives to attract and motivate eligible employees whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company’s future perfor

Amendment No. 2 to the Equity Distribution Agreement, dated October 31, 2024, by and between Nurix Therapeutics, Inc. and Piper Sandler & Co.

Exhibit 10.1 AMENDMENT NO. 2 TO THE EQUITY DISTRIBUTION AGREEMENT October 31, 2024 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: This Amendment No. 2 to the Equity Distribution Agreement (this “Amendment”) is entered into as of the date first written above by Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), and Piper S

Up to $300,000,000 Common Stock

Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-280117 PROSPECTUS SUPPLEMENT (To Prospectus dated June 11, 2024) Up to $300,000,000 Common Stock We previously entered into an Equity Distribution Agreement dated August 4, 2021, as amended by Amendment No. 1 to the Equity Distribution Agreement dated July 11, 2024 and Amendment No. 2 to the Equity Distribution Agreement dated

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 31, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

Exhibit 99.1 Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur SAN FRANCISCO, October 16, 2024 (GLOBE NEWSWIRE) — Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointme

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 15, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

Fifth Amendment to Lease Agreement, dated September 13, 2024, by and between ARE-San Francisco No. 26 Owner, LLC and the Registrant

Exhibit 10.3 FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (this “Fifth Amendment”) is made as of September 13, 2024 (“Effective Date”), by and between ARE-SAN FRANCISCO NO. 26 OWNER, LLC, a Delaware limited liability company (“Landlord”), and NURIX THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated

Third Amendment to Lease Agreement, dated September 13, 2024, by and between ARE-San Francisco No. 19 Owner, LLC and the Registrant

Exhibit 10.4 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of September 13, 2024 (“Effective Date”), by and between ARE-SAN FRANCISCO NO. 19 OWNER, LLC, a Delaware limited liability company (“Landlord”), and NURIX THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated

Third Amendment to Lease Agreement, dated March 2, 2021, by and between ARE-San Francisco No. 26 Owner, LLC and the Registrant

Exhibit 10.1 THIRD AMENDMENT TO LEASE THIS THIRD AMENDMENT TO LEASE (this “Third Amendment”) is made as of March 2, 2021, by and between ARE-SAN FRANCISCO NO. 26, LLC, a Delaware limited liability company (“Landlord”), and NURIX THERAPEUTICS, INC., a Delaware corporation, formerly known as Nurix, Inc. (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement dated

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 11, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDA Initiated Phase 1b dose expansion of NX-5948 in Waldenstrom’s macroglobulinemia, follicular lymphoma and marginal zone lymphoma patien

, by and between ARE-San Francisco No. 26 Owner, LLC and the Registrant

Exhibit 10.2 FOURTH AMENDMENT TO LEASE THIS FOURTH AMENDMENT TO LEASE (this “Fourth Amendment”) is made as of April 30, 2021, by and between ARE-SAN FRANCISCO NO. 26, LLC, a Delaware limited liability company (“Landlord”), and NURIX THERAPEUTICS, INC., a Delaware corporation, formerly known as Nurix, Inc. (“Tenant”). RECITALS A. Landlord and Tenant are now parties to that certain Lease Agreement d

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 5, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi

Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation September 2024 2 Important notice and disclaimers This presentation contains statements that relate to future events and expectations and as

Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation September 2024 2 Important notice and disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Amendment No. 1 to the Equity Distribution Agreement, dated July 11, 2024, by and between the Registrant and Piper Sandler & Co.

Exhibit 10.1 AMENDMENT NO. 1 TO THE EQUITY DISTRIBUTION AGREEMENT July 11, 2024 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: This Amendment No. 1 to the Equity Distribution Agreement (this “Amendment”) is entered into as of the date first written above by Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), and Piper Sand

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phi

CALCULATION OF FILING FEE TABLE Form 424(b)(5) (Form Type) Nurix Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of Each Class of Securities to be Registered Fee Calcu

Exhibit 107 CALCULATION OF FILING FEE TABLE Form 424(b)(5) (Form Type) Nurix Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC.

Up to $150,000,000 Common Stock

Table of Contents Filed pursuant to Rule 424(b)(5) Registration No. 333-280117 PROSPECTUS SUPPLEMENT (To Prospectus dated June 11, 2024) Up to $150,000,000 Common Stock We previously entered into an Equity Distribution Agreement dated August 4, 2021, as amended by Amendment No. 1 to the Equity Distribution Agreement dated July 11, 2024 (Equity Distribution Agreement) with Piper Sandler & Co. (Pipe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 11, 2024 NURIX THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 11, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) Objective response rate of 69.2% obs

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024) Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK inhibitor resistance mutations Clinical responses

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 16, 2024 NURIX THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 16, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati

Nurix Therapeutics NX-5948 Clinical Update European Hematology Association Congress EHA2024 June 16, 2024 2 Important notice and disclaimers This presentation contains statements that relate to future events and expectations and as such constitute fo

Nurix Therapeutics NX-5948 Clinical Update European Hematology Association Congress EHA2024 June 16, 2024 2 Important notice and disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Form of Debt Security

Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] NURIX THERAPEUTICS, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS     % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS     % OF ITS PRINCIPAL AMOUNT, THE YIE

Form of Indenture

Exhibit 4.4 NURIX THERAPEUTICS, INC. And           , as Trustee INDENTURE Dated as of     , TABLE OF CONTENTS ARTICLE 1 – DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2 – THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITI

As filed with the Securities and Exchange Commission on June 11, 2024

Table of Contents As filed with the Securities and Exchange Commission on June 11, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Nurix Therapeutics, Inc.

NRIX / Nurix Therapeutics, Inc. / BlackRock Inc. Passive Investment

SC 13G/A 1 us67080m1036060724.txt us67080m1036060724.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) Nurix Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 67080M103 - (CUSIP Number) May 31, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 20, 2024 NURIX THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 20, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio

Underwriting Agreement by and among Nurix Therapeutics, Inc. and J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated as Representatives of the several underwriters, dated April 11, 2024

Exhibit 1.1 Execution Version NURIX THERAPEUTICS, INC. 10,166,667 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,500,100 Shares of Common Stock Underwriting Agreement April 11, 2024 J.P. Morgan Securities LLC Piper Sandler & Co. Stifel, Nicolaus & Company, Incorporated As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madiso

Form of Pre-funded Warrant

EXHIBIT 4.1 NURIX THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [•] (subject to adjustment) Warrant No. [•] Original Issue Date: April [•], 2024 Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [•] or its registered assigns (the “Holder”

$450,000,000 Nurix Therapeutics, Inc. Common Stock, Preferred Stock, Debt Securities, Warrants, Subscription Rights and Units

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258448 PROSPECTUS SUPPLEMENT (To prospectus dated April 6, 2023) 10,166,667 shares of common stock Pre-funded warrants to purchase 1,500,100 shares of common stock We are offering 10,166,667 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of co

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

EXHIBIT 99.1 Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering SAN FRANCISCO, April 11, 2024 – Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share. In addition, and in lieu of common stock, Nurix is offering to certain invest

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 11, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizat

$450,000,000 Nurix Therapeutics, Inc. Common Stock, Preferred Stock, Debt Securities, Warrants, Subscription Rights and Units

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258448 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanyi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 10, 2024 NURIX THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 10, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 29, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC.

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Target

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Targeted Protein Degrader of STAT6 Presented new case studies on NX-5948 demonstrating clinical responses in patients with CNS lym

Sixth Amendment to Collaboration and License Agreement, dated March 6, 2024, by and between the Registrant and Genzyme Corporation

Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. SIXTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Sixth Amendment to Collaboration and License Agreement (this “Amendment”) is entered into as of March 6, 2024 (the “Amendment Dat

Second Amendment to Lease Agreement, dated March 25, 2024, by and between ARE-San Francisco No. 19 Owner, LLC and the Registrant

Exhibit 10.2 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this “Second Amendment”) is made as of March 25, 2024 (“Effective Date”), by and between ARE-SAN FRANCISCO NO. 19 OWNER, LLC, a Delaware limited liability company (“Landlord”), and NURIX THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant entered into that certain Lease Agreement dated as of J

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 9, 2024 NURIX THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 9, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Onl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by

ARS

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial Nurix cleared to introduce new chirally controlled NX-2127 drug product and resume enrollment of new patients into the study

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 Trial Nurix cleared to introduce new chirally controlled NX-2127 drug product and resume enrollment of new patients into the study SAN FRANCISCO, March 11, 2024 – Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation dru

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizat

As filed with the Securities and Exchange Commission on February 15, 2024

As filed with the Securities and Exchange Commission on February 15, 2024 Registration No.

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update NX-5948 received fast track designation from the FDA NX-5948 showed positive results in Phase 1 clinical trial establishing a robust foun

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update NX-5948 received fast track designation from the FDA NX-5948 showed positive results in Phase 1 clinical trial establishing a robust foundation for advancement in CLL Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39398 NURIX THERAPEUT

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 15, 2024 NURIX THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 15, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi

Fifth Amendment to Collaboration and License Agreement, dated November 3, 2023, by and between the Registrant and Genzyme Corporation

Exhibit 10.24 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. FIFTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Fifth Amendment to Collaboration and License Agreement (this “Amendment”) is entered into as of November 3, 2023 (the “Amendment

Collaboration and License Agreement, dated September 6, 2023, by and between the Registrant and Seagen Inc.

Exhibit 10.25 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. COLLABORATION AND LICENSE AGREEMENT by and between NURIX THERAPEUTICS, INC. and SEAGEN INC. dated as of September 6, 2023 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 ARTICLE 2 DEGRADER TARGE

Compensation Recovery Policy

Exhibit 97.1 COMPENSATION RECOVERY POLICY THIS POLICY WAS ADOPTED BY THE BOARD AND IS EFFECTIVE AS OF JULY 25, 2023. PURPOSE The Board of Directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”) has determined that it is in the best interests of the Company and its stockholders to adopt this Compensation Recovery Policy (this “Policy”) to enable the Company to recover from specified cur

NRIX / Nurix Therapeutics, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

SC 13G/A 1 nrix13gadec23.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) NURIX THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 67080M103 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule

NRIX / Nurix Therapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Nurix therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

Joint Filing Agreement

EX-99.1 2 tm245846d24ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 p

NRIX / Nurix Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment

SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No.

NRIX / Nurix Therapeutics, Inc. / SANDS ARTHUR T - SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nurix Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

NRIX / Nurix Therapeutics, Inc. / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

NRIX / Nurix Therapeutics, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SC 13G 1 tv01578-nurixtherapeuticsinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Nurix Therapeutics Inc Title of Class of Securities: Common Stock CUSIP Number: 67080M103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursu

NRIX / Nurix Therapeutics, Inc. / MORGAN STANLEY - MS INITIAL Passive Investment

SC 13G 1 NurixTherapeuticsIncNRIX.txt MS INITIAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Nurix Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 67080M103 - (CUSIP Number) December 31, 2023 - (Date Of Event which Requires Filing of this Statement) Check the appr

NRIX / Nurix Therapeutics, Inc. / WASATCH ADVISORS INC Passive Investment

SCHEDULE 13G Amendment No. 1 Name of Issuer: Nurix Therapeutics, Inc. Title of Class of Securities: Common Stock CUSIP Number: 67080M103 Item 1: Reporting Person: Wasatch Advisors LP 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 2,749,745 Item 6: Shared Voting Po

NRIX / Nurix Therapeutics, Inc. / ARK Investment Management LLC - SC 13G Passive Investment

SC 13G 1 tm244117d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Nurix Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the

NRIX / Nurix Therapeutics, Inc. / BlackRock Inc. Passive Investment

SC 13G/A 1 us67080m1036012424.txt us67080m1036012424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) Nurix Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 67080M103 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropria

NRIX / Nurix Therapeutics, Inc. / STATE STREET CORP Passive Investment

SC 13G/A 1 NurixThInc.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING NURIX THERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 67080M103 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO

Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation January 2024 Exhibit 99.1 2 Important notice and disclaimers This presentation contains statements that relate to future events and expectat

nrix-202401088xkex991 Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation January 2024 Exhibit 99.

Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases Positive Phase 1 data presented at American Society of Hematology supports prioritizing the acceleration

Exhibit 99.2 [Nurix logo] Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases Positive Phase 1 data presented at American Society of Hematology supports prioritizing the acceleration of enrollment of NX-5948 in leukemia and lymphoma Strategic collaborations in small molecule, targeted protein degradation w

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 NURIX THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2024 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiza

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 11, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting Positive preliminary efficacy data with a favorab

Exhibit 99.1 [Nurix logo] Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton’s Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting Positive preliminary efficacy data with a favorable safety profile support plans to develop NX-5948 broadly in chronic lymphocytic leukemia (CLL) Rapid durable complete resp

Important notice and disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or

EX-99.1 Exhibit 99.1 Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation November 2023 Important notice and disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if u

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2023 NURIX THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi

Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial Currently enrolled patients may continue receiving NX-2127

Exhibit 99.1 Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial Currently enrolled patients may continue receiving NX-2127 SAN FRANCISCO, CA, November 1, 2023 – Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today ann

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 1, 2023 NURIX THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 1, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

Collaboration and License Agreement, dated September 6, 2023, by and between the Registrant and Seagen Inc.

Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. COLLABORATION AND LICENSE AGREEMENT by and between NURIX THERAPEUTICS, INC. and SEAGEN INC. dated as of September 6, 2023 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 ARTICLE 2 DEGRADER TARGET

Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Announced strategic collaboration with Seagen to develop a portfolio of Degrader-Antibody Conjugates, resulting in a $60 million upfront payment Ac

Exhibit 99.1 Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Announced strategic collaboration with Seagen to develop a portfolio of Degrader-Antibody Conjugates, resulting in a $60 million upfront payment Achieved an additional $8 million in research milestones for the quarter, resulting in milestone and license fee payments totaling $35.5 mi

First Amendment to Lease Agreement, dated June 28, 2023, by and between ARE-San Francisco No. 19 Owner, LLC and the Registrant

Exhibit 10.1 FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of June 28, 2023 (the “Effective Date”), by and between ARE-SAN FRANCISCO NO. 19 OWNER, LLC, a Delaware limited liability company (“Landlord”), and NURIX THERAPEUTICS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant entered into that certain Lease Agreement dated as of J

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 12, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

First Amendment to Lease Agreement, dated August 25, 2023, by and between 8800 Technology Forest PL, LLC and the Registrant

Exhibit 10.2 FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (this "First Amendment") is made as of August 25, 2023, by and between 8800 TECHNOLOGY FOREST PL, LLC, a Delaware limited liability company ("Landlord"), and NURIX THERAPEUTICS, INC., a Delaware corporation ("Tenant"). RECITALS A. Landlord and Tenant are parties to that certain Lease Agreement dated as of March

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 6, 2023 NURIX THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 6, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin’s lymphomas Presented data highlighting the potent cellular activity of both NX-59

Exhibit 99.1 Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Announced Phase 1b expansion cohorts for NX-2127 in non-Hodgkin’s lymphomas Presented data highlighting the potent cellular activity of both NX-5948 and NX-2127 against BTKi resistance mutations Received $20 million licensing payment from Gilead for NX-0479, an oral IRAK4 degrader f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 13, 2023 NURIX THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 13, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2023 NURIX THERAPEUTICS, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organization

Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment Expanded

Exhibit 99.1 Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK4, resulting in a $20 million payment Expanded therapeutic area potential of protein degradation pipeline with Gilead in rheumatoid arthritis and other inflammatory diseases Achieved a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 13, 2023 NURIX THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 13, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 5, 2023 NURIX THERAPEUTICS,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 5, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Onl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________ FORM 10-K ___________________________________________________________________________________

nurixtherapeuticsincx20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant  ☐ Check the appropriate box:  ☐ Preliminary Proxy Statement  ☐ Confidential, for Use of the Commission Only (as permitted by

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2023 NURIX THERAPEUTICS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 13, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizat

NRIX / Nurix Therapeutics Inc / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Joint Filing Agreement

Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the undersigned hereby agree to the joint filing on behalf of each of them of a Statement on Schedule 13G (including any and all amendments thereto, the “Schedule 13G”) relating to the Common Stock, $0.001 par value per share, of Nurix Therapeutics, In

NRIX / Nurix Therapeutics, Inc. Common stock / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment

SC 13G/A 1 tm234999d18sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Nurix Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appro

NRIX / Nurix Therapeutics, Inc. Common stock / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

SC 13G/A 1 nrix13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) NURIX THERAPEUTICS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 67080M103 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule

NRIX / Nurix Therapeutics, Inc. Common stock / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

NRIX / Nurix Therapeutics, Inc. Common stock / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 d441085dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Nurix Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Ch

NRIX / Nurix Therapeutics, Inc. Common stock / Redmile Group, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Nurix therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs

NRIX / Nurix Therapeutics, Inc. Common stock / STATE STREET CORP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING NURIX THERAPEUTICS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 67080M103 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE IS

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignanci

Exhibit 99.1 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update Demonstrated NX-2127 overcomes BTK inhibitor resistance mutations and provides clinical benefit to patients with hematological malignancies Achieved significant milestones in wholly owned clinical programs and partnered preclinical programs Maintained strong financial posit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended November 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-3939

As filed with the Securities and Exchange Commission on February 9, 2023

Table of Contents As filed with the Securities and Exchange Commission on February 9, 2023 Registration No.

Filing Fee Table

EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Nurix Therapeutics, Inc.

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Tables FORM S-8 (Form Type) NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001

Description of Registrant’s Securities

Exhibit 4.3 DESCRIPTION OF CAPITAL STOCK The following summary of the terms of our capital stock is based upon our restated certificate of incorporation, our amended and restated bylaws and applicable provisions of the Delaware General Corporation Law (DGCL). This summary is not complete, and is qualified by reference to our restated certificate of incorporation and our amended and restated bylaws

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 9, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

As filed with the Securities and Exchange Commission on February 9, 2023

Table of Contents As filed with the Securities and Exchange Commission on February 9, 2023 Registration No.

As filed with the Securities and Exchange Commission on February 9, 2023

As filed with the Securities and Exchange Commission on February 9, 2023 Registration No.

NRIX / Nurix Therapeutics, Inc. Common stock / WASATCH ADVISORS INC Passive Investment

SCHEDULE 13G Amendment No. Name of Issuer: Nurix Therapeutics, Inc. Title of Class of Securities: Common Stock CUSIP Number: 67080M103 Item 1: Reporting Person: Wasatch Advisors LP 87-0319391 Item 2: Check Box If Member of Group: Not Applicable Item 3: SEC Use Item 4: Place of Organization: Utah Items 5-8: Number of Shares Owned With: Item 5: Sole Voting Power: 2,538,632 Item 6: Shared Voting Powe

NRIX / Nurix Therapeutics, Inc. Common stock / BlackRock Inc. Passive Investment

SC 13G/A 1 us67080m1036012523.txt us67080m1036012523.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) Nurix Therapeutics, Inc. - (Name of Issuer) Common Stock - (Title of Class of Securities) 67080M103 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropria

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2023 NURIX THERAPEUTIC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2023 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiza

Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by i

Exhibit 99.2 Nurix Therapeutics Advances Promising Targeted Protein Modulation Pipeline and Outlines 2023 Strategic Priorities Nurix leads targeted protein modulation field with its wholly owned clinical stage programs and two strategic collaborations fueled by its DELigase platform Clinical data updates planned for Nurix’s two first-in-class BTK degraders in 2023 Clinical data update planned for

Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or

Exhibit 99.1 Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine Investor Presentation January 2023 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or if used in th

Amended and Restated Bylaws

Exhibit 3.1 NURIX THERAPEUTICS, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS As Amended and Restated on December 15, 2022 NURIX THERAPEUTICS, INC. (a Delaware corporation) AMENDED AND RESTATED BYLAWS TABLE OF CONTENTS ARTICLE I: STOCKHOLDERS 1 Section 1.1: Annual Meetings 1 Section 1.2: Special Meetings 1 Section 1.3: Notice of Meetings 1 Section 1.4: Adjournments 1 Section 1.5: Quoru

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 15, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic

EX-99.1 Exhibit 99.1 Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase (BTK) mutational status BTK mutations conferring resis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 12, 2022 NURIX THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 12, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organi

Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or

EX-99.2 Exhibit 99.2 Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine ASH Event Presentation December 12, 2022 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or

Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When or

Exhibit 99.1 Leader in Targeted Protein Modulation The First BTK Degraders in Hematologic Malignancies: The Latest from the Clinic Arthur T. Sands, M.D., Ph.D. President & CEO 5th Annual TPD Summit Boston, MA October 26th, 2022 1 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking statements wit

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 26, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiz

Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit Complete response observed and ongoing in a pati

Exhibit 99.2 Nurix Therapeutics Reports Case Study of Patient with Aggressive Non-Hodgkin?s Lymphoma (NHL) Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation (TPD) Summit Complete response observed and ongoing in a patient with multiply relapsed/refractory diffuse large B cell lymphoma (DLBCL) Dual BTK degradation and immunomodulatory activity achieved b

Third Amendment to Collaboration and License Agreement, dated July 7, 2022, by and between the Registrant and Genzyme Corporation

Exhibit 10.5 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRD Amendment to collaboration AND LICENSE AGREEMENT This Third Amendment to Collaboration and License Agreement (this ?Amendment?) is entered into as of July 7, 2022 (the ?Amendment Date?) by and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended August 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC.

First Amendment to Collaboration, Option and License Agreement, dated August 13, 2019, by and between the Registrant and Gilead Sciences, Inc.

Exhibit 10.2 FIRST AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENT This First Amendment to Collaboration, Option and License Agreement (this ?First Amendment?), dated August 13, 2019 (the ?First Amendment Effective Date?), is by and between Nurix Therapeutics, Inc., a Delaware corporation (?Nurix?) and Gilead Sciences, Inc., a Delaware corporation (?Gilead?). RECITALS WHEREAS, Nurix and G

Second Amendment to Collaboration, Option and License Agreement, dated September 9, 2022, by and between the Registrant and Gilead Sciences, Inc.

Exhibit 10.3 SECOND AMENDMENT TO COLLABORATION, OPTION AND LICENSE AGREEMENT This Second Amendment to Collaboration, Option and License Agreement (this ?Second Amendment?), dated September 9, 2022 (the ?Second Amendment Effective Date?), is by and between Nurix Therapeutics, Inc., a Delaware corporation (?Nurix?) and Gilead Sciences, Inc., a Delaware corporation (?Gilead?). RECITALS WHEREAS, Gilea

Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update Completed two registered direct offerings in July raising gross proceeds of $95 million Maintained strong financial position with $413.6 million in

Exhibit 99.1 Nurix Therapeutics Reports Third Quarter Fiscal 2022 Financial Results and Provides a Corporate Update Completed two registered direct offerings in July raising gross proceeds of $95 million Maintained strong financial position with $413.6 million in cash and marketable securities as of August 31, 2022 Expanded leadership team and board of directors with experienced industry leaders A

Fourth Amendment to Collaboration and License Agreement, dated August 11, 2022, by and between the Registrant and Genzyme Corporation

Exhibit 10.6 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FOURTH Amendment to collaboration AND LICENSE AGREEMENT This Fourth Amendment to Collaboration and License Agreement (this ?Amendment?) is entered into as of August 11, 2022 (the ?Amendment Date?) by

Second Amendment to Collaboration and License Agreement, dated December 16, 2021, by and between the Registrant and Genzyme Corporation

EX-10.4 4 nrix-ex104180.htm EX-10.4 Exhibit 10.4 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE OF INFORMATION THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SEcond Amendment to collaboration AND LICENSE AGREEMENT This Second Amendment to Collaboration and License Agreement (this “Amendment”) is entered into as of Decem

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 6, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organiza

Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors

Exhibit 99.1 Nurix Therapeutics Appoints Leading Industry Strategist Edward C. Saltzman to its Board of Directors SAN FRANCISCO, September 14, 2022 ? Nurix Therapeutics , Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Edward C. Saltzman to its board of directors. Mr. Saltzman has over 30 years of drug

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 12, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organ

Nurix Therapeutics Announces $40 Million Registered Direct Offering

Exhibit 99.2 Nurix Therapeutics Announces $40 Million Registered Direct Offering SAN FRANCISCO, July 8, 2022 ? Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with two healthcare-focused investment funds to sell, in a registered direct offering,

Calculation of Filing Fee Tables (Form Type) Nurix Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Ru

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. Pre-Funded Warrants to Purchase up to 2,869,440 Shares of Common Stock

Table of Contents As filed pursuant to Rule 424(b)(5) Registration No. 333-258448 PROSPECTUS SUPPLEMENT (To prospectus dated August 4, 2021) Nurix Therapeutics, Inc. Pre-Funded Warrants to Purchase up to 2,869,440 Shares of Common Stock We are offering pre-funded warrants (the ?Pre-funded Warrants?) to purchase up to 2,869,440 shares of our common stock, $0.001 par value per share (our ?common sto

Form of Securities Purchase Agreement

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of July [ ], 2022, between Nurix Therapeutics, Inc., a corporation incorporated under the laws of the state of Delaware (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?).

Form of Pre-funded Warrant

Exhibit 4.1 NURIX THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [?] (subject to adjustment) Warrant No. [?] Original Issue Date: July [?], 2022 Nurix Therapeutics, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [?] or its registered assigns (the ?Holder?)

Nurix Therapeutics, Inc. Pre-Funded Warrants to Purchase up to 3,945,480 Shares of Common Stock

Table of Contents As filed pursuant to Rule 424(b)(5) Registration No. 333-258448 PROSPECTUS SUPPLEMENT (To prospectus dated August 4, 2021) Nurix Therapeutics, Inc. Pre-Funded Warrants to Purchase up to 3,945,480 Shares of Common Stock We are offering pre-funded warrants (the ?Pre-funded Warrants?) to purchase up to 3,945,480 shares of our common stock, $0.001 par value per share (our ?common sto

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 7, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio

Calculation of Filing Fee Tables (Form Type) Nurix Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Ru

Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Nurix Therapeutics, Inc.

Nurix Therapeutics Announces $55 Million Registered Direct Offering

Exhibit 99.1 Nurix Therapeutics Announces $55 Million Registered Direct Offering SAN FRANCISCO, July 7, 2022 ? Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with an institutional investor to sell, in a registered direct offering, pre-funded wa

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 7, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC.

Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update NX-2127 advanced to Phase 1b in CLL based on promising data in Phase 1a clinical trial First patient dosed in NX-5948 Phase 1a clinical trial for

Exhibit 99.1 Nurix Therapeutics Reports Fiscal Second Quarter 2022 Financial Results and Provides a Corporate Update NX-2127 advanced to Phase 1b in CLL based on promising data in Phase 1a clinical trial First patient dosed in NX-5948 Phase 1a clinical trial for certain B-cell malignancies NX-1607 IND cleared FDA for expansion of enrollment to U.S. clinical sites for patients with solid tumors Res

NRIX / Nurix Therapeutics, Inc. Common stock / Deep Track Capital, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 26, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio

Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development Data to be discussed at Nurix R&D Day at 8:00 a.m. ET today May 26

Exhibit 99.2 Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development Data to be discussed at Nurix R&D Day at 8:00 a.m. ET today May 26 SAN FRANCISCO, May 26, 2022 (GLOBAL NEWSWIRE) ? Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today anno

Welcome and Introduction Arthur T Sands, MD, PhD President, CEO and Board Director Nurix Therapeutics 2

Exhibit 99.1 Leader in Targeted Protein Modulation Nurix Therapeutics Blazing a New Path in Medicine R&D Day New York, NY May 26, 2022 Welcome and Introduction Arthur T Sands, MD, PhD President, CEO and Board Director Nurix Therapeutics 2 Important Notice and Disclaimers This presentation contains statements that relate to future events and expectations and as such constitute forward-looking state

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 15, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizatio

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organization

Lease Agreement, dated as of March 1, 2022, between 8800 Technology Forest Pl, LLC and the Registrant

Exhibit 10.1 LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made this 1 day of March, 2022 (?Effective Date?), between 8800 TECHNOLOGY FOREST PL, LLC, a Delaware limited liability company (?Landlord?), and NURIX THERAPEUTICS, INC., a Delaware corporation (?Tenant?). Building: Building 100, 8800 Technology Forest Place, The Woodlands, Texas 77381 Premises: That portion of the Building, comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended February 28, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39398 NURIX THERAPEUTICS, INC.

Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update Dosed first patient in the Phase 1 trial of DeTIL-0255, Nurix’s drug-enhanced tumor infiltrating lymphocyte (TIL) program Awarded Innovation Passpo

Exhibit 99.1 Nurix Therapeutics Reports Fiscal First Quarter 2022 Financial Results and Provides a Corporate Update Dosed first patient in the Phase 1 trial of DeTIL-0255, Nurix?s drug-enhanced tumor infiltrating lymphocyte (TIL) program Awarded Innovation Passport for Entry into Innovative Licensing and Access Pathway (ILAP) in the United Kingdom for NX-1607 Reports strong financial position with

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 7, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 d509090ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of t

our Definitive Proxy Statement on Schedule 14A (other than the information contained therein that is furnished rather than filed), filed with the SEC on March 25, 2022;

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 2, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 1, 2022 NURIX THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-39398 27-0838048 (State or Other Jurisdiction of Incorporation or Organizati

NRIX / Nurix Therapeutics, Inc. Common stock / Third Rock Ventures III, L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Nurix Therapeutics, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 67080M103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

NRIX / Nurix Therapeutics, Inc. Common stock / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Nurix Therapeutics, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 67080M103 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sche

POWER OF ATTORNEY

EXHIBIT 24 POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Kevin Gillis his true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his capacity as a direct or indirec

Joint Filing Agreement

EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be